Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...

Over the last 7 days, the United States market has dropped 5.6%, yet it remains up by 3.3% over the past year, with earnings projected to grow by 14% annually in the coming years. In this context, ...

BofA analyst Jason Zemansky lowered the firm’s price target on Travere Therapeutics (TVTX) to $27 from $31 and keeps a Buy rating on the shares ...

Today, a brief rundown of news involving Sarepta Therapeutics, Novartis and Allakos, as well as updates from CSL Behring and Roche that you may have missed.

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a ...

Elizabeth Fraley, Founder and CEO of Kinder Ready, continues to make a meaningful impact by guiding families through one of the most crucial decisions in their child's academic journey: selecting the ...

SiriusXM  will release its first quarter 2025 operating and financial results on Thursday, May 1, and will hold an investor call that same day at 8:00 a.m. ET. A live webcast will be available on the ...